FDA Signals Greater Scrutiny of Foreign Clinical Data
FDA doubles down on the inspectability and integrity of foreign clinical data
On September 2, 2026, The U.S. Food and Drug Administration published an article with an unequivocal title: “Good Clinical Practices Are Not Optional.”
The article was written by senior leaders from four FDA centers: the Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research, Center for Devices and Radiological Health, and Oncology Center of Excellence. It addresses FDA’s concerns about human-subject protections and the reliability of clinical data generated outside the United States.
The publication is not a regulation or guidance, and it does not establish a new GCP standard. FDA says directly that its position is not new policy. Foreign clinical studies not conducted under an IND or IDE have long been required to meet applicable GCP expectations, including independent ethical review and informed consent, if their data are to support an FDA regulatory decision.
So why does the article matter? Because FDA is not merely restating the standard. It is explaining why the agency believes that the standard is being tested, identifying the circumstances causing concern, and describing specific actions it intends to take. The importance lies less in a change to the requirements than in what the statement reveals about FDA’s inspection and review priorities.
Not new requirements, but a clear regulatory signal
FDA’s concern centers on its ability to validate the evidence submitted by sponsors. As clinical research has become increasingly global, FDA has encountered challenges accessing foreign study sites. In some cases, access has been denied. In others, access has been conditional on agreements that would limit the scope or conduct of an inspection. FDA also notes that a host country’s regulatory capacity or authority may not always provide oversight commensurate with the agency’s expectations.
The article is particularly focused on foreign clinical data generated outside an IND or IDE. FDA states that it plans to apply more rigorous and systematic review to these studies and sites, with particular attention to Early Feasibility Studies, Phase 1 studies, and jurisdictions where geopolitical conditions or documented human-rights concerns may make it difficult to establish that informed consent was freely and voluntarily given.
FDA also points to serious data-integrity concerns identified through audits of clinical trial conduct, including fabricated participants, falsified health conditions or laboratory results, and concealed adverse events. These examples establish the stakes behind the agency’s message. If FDA cannot validate that clinical data were generated in accordance with GCP, it may refuse to accept the data. If the remaining evidence cannot support the application, marketing authorization may be denied, withheld, or rescinded.
What FDA says it intends to do
The most consequential part of the article is FDA’s description of the actions it plans to take.
Expand foreign inspection coverage
FDA plans to add resources for foreign Bioresearch Monitoring (BIMO) inspections. This includes more Phase 1 and early-stage trials. Inspections may also cover additional trials at the same facility.
Update risk-based site-selection criteria
FDA plans to revise its site-selection criteria to better reflect compliance risks associated with specific countries or regions.
Increase scrutiny of studies outside an IND or IDE
FDA plans to use information requests, reanalysis, and inspections to determine whether studies met GCP expectations before relying on their data.
Train reviewers to recognize and escalate concerns
FDA will provide additional training to help reviewers identify potential GCP, informed consent, and data integrity concerns at clinical trial sites.
Increase transparency
FDA intends to communicate more systematically when sites, personnel, records, or data are unavailable for inspection. It also plans to make more information about certain foreign inspection findings publicly available, as appropriate.
Engage sponsors earlier
FDA plans to discuss data provenance and the IND or IDE status of foreign studies earlier in development. These discussions may occur during pre-IND meetings, Type B meetings, and Q-submissions.
Taken together, these actions make the article more than a general affirmation of GCP. FDA is giving sponsors advance notice that inspectability, data provenance, informed consent, and the reliability of foreign clinical data are likely to receive greater attention during both inspection and regulatory review.
What should trial sponsors take from this?
FDA’s message is not that foreign clinical data are inherently unreliable. The article explicitly acknowledges that many institutions outside the United States produce clinical data of the highest quality. Nor does it suggest that every foreign site presents the same level of risk. The agency’s stated position is that geography does not change the evidentiary standard.
The practical takeaway is that the ability to inspect and validate clinical data cannot be treated as an administrative detail at the end of development. FDA tells sponsors to consider the inability to inspect a site or access relevant data as a material factor in regulatory strategy. It also urges sponsors to plan development programs in settings where agency access will not be impeded from day one.
That direction may warrant a closer look at how inspectability and data provenance are considered in country and site selection, the use of foreign studies outside an IND or IDE, informed-consent oversight, and regulatory planning. It may also require stronger connections among the teams that understand where the data originated, the conditions under which they were generated, and the records available to demonstrate that the trial was conducted appropriately.
This is not a call to add controls indiscriminately or to treat every global study as a heightened compliance concern. It is a reason to ask whether the risks FDA has identified are understood early enough to influence development decisions, rather than discovered when the agency attempts to inspect a site or validate data supporting an application.
Questions sponsors should consider now
- Does our development program rely on foreign clinical studies or sites outside an IND or IDE, and is that status visible to the teams making regulatory decisions?
- Have we considered whether FDA could obtain timely and meaningful access to the sites, personnel, source data, consent records, and other relevant records?
- Can we clearly explain the provenance of the critical foreign clinical data expected to support the application?
- Are there local, contractual, technological, or geopolitical conditions that could constrain inspection access or the availability of relevant evidence?
- Are potential concerns involving informed consent, data integrity, or inspection access escalated early enough to inform regulatory strategy?
The signal matters even when the standard has not changed
FDA has not created a new GCP requirement through this article. What it has done is make its concern, intended focus, and willingness to act unusually clear. For clinical trial sponsors, that distinction matters. The appropriate response is not to treat the article as new guidance, but neither should it be dismissed as a restatement of familiar principles.
It is a regulatory signal that FDA intends to look more closely at whether foreign clinical data are ethically derived, accessible for inspection, and reliable enough to support its decisions. Sponsors that understand that signal now have an opportunity to examine those risks while there is still time to address them.
Sources
- U.S. Food and Drug Administration. “Good Clinical Practices Are Not Optional: The FDA’s Commitment to Human Subject Protections and Gold Standard Science in an Era of Global Clinical Research.” September 2026.
- U.S. Food and Drug Administration. “FDA Acceptance of Foreign Clinical Studies Not Conducted Under an IND: Frequently Asked Questions.”
- U.S. Food and Drug Administration. “Processes and Practices Applicable to Bioresearch Monitoring Inspections: Guidance for Industry.” December 2025.